复星医药(600196.SH):HLX10联合化疗用于治疗未接受过治疗的广泛期小细胞肺癌启动III期临床研究
格隆汇9月12日丨复星医药(600196.SH)公布,近日,公司控股子公司上海复宏汉霖生物技术股份有限公司(“复宏汉霖”)于中国境内(不包括港澳台地区,下同)就HLX10(即重组抗PD-1人源化单克隆抗体注射液;以下简称“该新药”)联合化疗(卡铂-依托泊苷)用于治疗未接受过治疗的广泛期小细胞肺癌(以下简称“该治疗方案”)启动III期临床研究。
新药为集团自主研发的创新型治疗用生物制品,主要用于实体瘤治疗,目前也正进一步探索慢性乙型肝炎治疗的可能性。
截至公告日,于中国境内上市的重组抗PD-1人源化单克隆抗体注射液包括默沙东制药有限公司的可瑞达®、美国百时美施贵宝公司的欧狄沃®等。根据IQVIA CHPA最新数据(由IQVIA提供,IQVIA是全球领先的医药健康产业专业信息和战略咨询服务提供商),2018年度,重组抗PD-1人源化单克隆抗体注射液于中国境内销售额约人民币2668万元。
截至2019年8月,集团现阶段针对该新药的累计研发投入人民币约19564万元(未经审计)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.